Are Alzheimer's drugs good for other memory problems?

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter
The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

UCLA School of Nursing

New insights in using Alzheimer's drugs for other memory problems shows why these medications are no simple memory patch. 

---

When people experience memory loss that looks a little like Alzheimer's but isn't, doctors diagnose it as "Mild Cognitive Impairment (MCI)". Some prescribe the Alzheimer's drug donepezil (Aricept®). New research shows why it should not be prescribed for people with mild cognitive impairment (MCI) without a genetic test.

UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation — the K-variant of butyrylcholinesterase, or BChE-K — donezpezil could accelerate cognitive decline.

When It Isn't Alzheimer's

Mild cognitive impairment is a transitional state between normal age-related changes in cognition and dementia. Because many people with the condition display symptoms similar to those caused by Alzheimer’s disease, some physicians prescribe donepezil, which is marketed under the brand name Aricept and is the most-prescribed medication for Alzheimer’s. Donepezil was tested as a possible treatment for mild cognitive impairment in a large, federally funded study published in 2005, but it was not approved by the FDA. Still, doctors have often prescribed the drug “off-label” — meaning that it is not approved for that specific disorder — for their patients with mild cognitive impairment.

Worse Instead of Better

From data collected during the 2005 trial, the researchers looked at the association between BChE-K and changes in cognitive function. Using two tests that measure cognitive impairment, the Mini-Mental State Examination and the Clinical Dementia Rating Sum of Boxes, they found that people with the genetic variation who were treated with donepezil had greater changes in their scores than those who took placebos. They also found that those who took donepezil had a faster cognitive decline than those who took the placebo.

Benefits versus Risks - Ask Your Doctor

Physicians are increasingly using personalized medicine, including pharmacogenetics — the study of how genetics affect a person’s response to a drug — to tailor their patients’ care. The findings reinforce the importance of physicians discussing the possible benefits and risks of this treatment with their patients. 

• SOURCE:
  UCLA School of Nursing
• AUTHORS:
  The study was led by Sophie Sokolow, an associate professor at the UCLA School of Nursing. Co-authors were Ziaohui Li, Lucia Chen, Kent Taylor and Jerome Rotter, all of UCLA.
• REFERENCE JOURNAL:
  The study was published in the Journal of Alzheimer’s Disease.
• FUNDING:
  The work was supported by the National Institute on Aging (grant 1K23AG05141601A1).